Generation of a tumor- and tissue-specific episomal non-viral vector system

BMC Biotechnology

Volumn 13, Issue , 2013, Pages

  Haase, Rudolf ^a   Magnusson, Terese ^a   Su, Baowei ^a   Kopp, Florian ^a   Wagner, Ernst ^a   Lipps, Hans ^b   Baiker, Armin ^c   Ogris, Manfred ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c Bavarian Health and Food Safety Authority   (Germany)

Author keywords

AFP; Episomal; pDNA; SM22; Tissue specific Replication; Tumor Targeting

Indexed keywords

AFP; EPISOMAL; PDNA; SM22; TISSUE SPECIFICS; TUMOR TARGETING;

CELL CULTURE; GENE TRANSFER; GENES; MUSCLE; PLANTS (BOTANY); TRANSCRIPTION; TUMORS;

VECTORS;

ALPHA FETOPROTEIN; GENE THERAPY AGENT; NONVIRAL VECTOR; POLYETHYLENEIMINE; TRANSGELIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CONTROLLED STUDY; ENHANCER REGION; EPISOME; GENE CASSETTE; GENE EXPRESSION; GENE REPLICATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIVER CELL CARCINOMA; MATRIX ATTACHMENT REGION; NONVIRAL GENE DELIVERY SYSTEM; PROMOTER REGION; TISSUE SPECIFICITY; TRANSGENE;

ALPHA-FETOPROTEINS; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HELA CELLS; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MATRIX ATTACHMENT REGIONS; MICE; MICE, NUDE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; PLASMIDS; PROMOTER REGIONS, GENETIC; TISSUE SCAFFOLDS; TRANSFECTION; TRANSGENES;

EID: 84878393801     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-13-49     Document Type: Article

References (53)

1. Ogris M, Wagner E. To be targeted: is the magic bullet concept a viable option for synthetic nucleic acid therapeutics?. Hum Gene Ther 2011, 22(7):799-807. 10.1089/hum.2011.065, 21563983.
2. Romano G. Systems for regulated or tissue-specific gene expression. Drug News Perspect 2004, 17(2):85-90. 10.1358/dnp.2004.17.2.829040, 15098061.
3. Maier P, von Kalle C, Laufs S. Retroviral vectors for gene therapy. Future Microbiol 2010, 5(10):1507-1523. 10.2217/fmb.10.100, 21073311.
4. Chavez CL, Calos MP. Therapeutic applications of the PhiC31 integrase system. Curr Gene Ther 2011, 11(5):375-381. 10.2174/156652311797415818, 21888619.
5. Izsvak Z, Hackett PB, Cooper LJ, Ivics Z. Translating sleeping beauty transposition into cellular therapies: victories and challenges. Bioessays 2010, 32(9):756-767. 10.1002/bies.201000027, 20652893.
6. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, Morillon E, Clappier E, Caccavelli L, Delabesse E, Beldjord K, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 2008, 118(9):3132-3142. 10.1172/JCI35700, 2496963, 18688285.
7. Piechaczek C, Fetzer C, Baiker A, Bode J, Lipps HJ. A vector based on the SV40 origin of replication and chromosomal S/MARs replicates episomally in CHO cells. Nucleic Acids Res 1999, 27(2):426-428. 10.1093/nar/27.2.426, 148196, 9862961.
8. Bode J, Kohwi Y, Dickinson L, Joh T, Klehr D, Mielke C, Kohwi-Shigematsu T. Biological significance of unwinding capability of nuclear matrix-associating DNAs. Science 1992, 255(5041):195-197. 10.1126/science.1553545, 1553545.
9. Baiker A, Maercker C, Piechaczek C, Schmidt SB, Bode J, Benham C, Lipps HJ. Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix. Nat Cell Biol 2000, 2(3):182-184. 10.1038/35004061, 10707091.
10. Jenke AC, Stehle IM, Herrmann F, Eisenberger T, Baiker A, Bode J, Fackelmayer FO, Lipps HJ. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. ProcNatlAcadSciUSA 2004, 101(31):11322-11327.
11. Jenke AC, Wilhelm AD, Orth V, Lipps HJ, Protzer U, Wirth S. Long-term suppression of hepatitis B virus replication by short hairpin RNA expression using the scaffold/matrix attachment region-based replicating vector system pEPI-1. Antimicrob Agents Chemother 2008, 52(7):2355-2359. 10.1128/AAC.00067-08, 2443918, 18474581.
12. Tsimbouri P, Drotar ME, Coy JL, Wilson JB. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene 2002, 21(33):5182-5187. 10.1038/sj.onc.1205490, 12140768.
13. Stehle IM, Scinteie MF, Baiker A, Jenke AC, Lipps HJ. Exploiting a minimal system to study the epigenetic control of DNA replication: the interplay between transcription and replication. Chromosome Res 2003, 11(5):413-421. 10.1023/A:1024962308071, 12971718.
14. Stehle IM, Postberg J, Rupprecht S, Cremer T, Jackson DA, Lipps HJ. Establishment and mitotic stability of an extra-chromosomal mammalian replicon. BMC Cell Biol 2007, 8:33. 10.1186/1471-2121-8-33, 1959191, 17683605.
15. Rupprecht S, Hagedorn C, Seruggia D, Magnusson T, Wagner E, Ogris M, Lipps HJ. Controlled removal of a nonviral episomal vector from transfected cells. Gene 2010, 466(1-2):36-42.
16. Eisenberger T, Lipps HJ, Mueller M, Baiker A. A human papillomavirus (HPV)-based pseudoviral gene delivery system for the Non-viral, episomally replicating vector PEPI-1. Gene TherMolBiol 2005, 9:371-376.
17. Haase R, Argyros O, Wong SP, Harbottle RP, Lipps HJ, Ogris M, Magnusson T, Vizoso Pinto MG, Haas J, Baiker A. pEPito: a significantly improved non-viral episomal expression vector for mammalian cells. BMC Biotechnol 2010, 10:20. 10.1186/1472-6750-10-20, 2847955, 20230618.
18. Ma XJ, Huang R, Kuang AR. AFP promoter enhancer increased specific expression of the human sodium iodide symporter (hNIS) for targeted radioiodine therapy of hepatocellular carcinoma. Cancer Invest 2009, 27(6):673-681. 10.1080/07357900802620885, 19241193.
19. Kemp PR, Osbourn JK, Grainger DJ, Metcalfe JC. Cloning and analysis of the promoter region of the rat SM22 alpha gene. Biochem J 1995, 310(Pt 3):1037-1043. 1135999, 7575400.
20. Lawson D, Harrison M, Shapland C. Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 1997, 38(3):250-257. 10.1002/(SICI)1097-0169(1997)38:3<250::AID-CM3>3.0.CO;2-9, 9384215.
21. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci USA 2008, 105(38):14342-14346. 10.1073/pnas.0804105105, 2567214, 18794521.
22. Navarro G, Maiwald G, Haase R, Rogach AL, Wagner E, de Ilarduya CT, Ogris M. Low generation PAMAM dendrimer and CpG free plasmids allow targeted and extended transgene expression in tumors after systemic delivery. J Control Release 2010, 146(1):99-105. 10.1016/j.jconrel.2010.04.030, 20438778.
23. Chollet P, Favrot MC, Hurbin A, Coll JL. Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J Gene Med 2002, 4(1):84-91. 10.1002/jgm.237, 11828391.
24. Qiu P, Li L. Histone acetylation and recruitment of serum responsive factor and CREB-binding protein onto SM22 promoter during SM22 gene expression. Circ Res 2002, 90(8):858-865. 10.1161/01.RES.0000016504.08608.B9, 11988486.
25. Deutsch HF. Chemistry and biology of alpha-fetoprotein. Adv Cancer Res 1991, 56:253-312.
26. Lazarevich NL. Molecular mechanisms of alpha-fetoprotein gene expression. Biochemistry (Mosc) 2000, 65(1):117-133.
27. Tomizawa M, Saisho H, Tagawa M. Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells. Anticancer Res 2003, 23(4):3273-3277.
28. Huang MC, Li KK, Spear BT. The mouse alpha-fetoprotein promoter is repressed in HepG2 hepatoma cells by hepatocyte nuclear factor-3 (FOXA). DNA Cell Biol 2002, 21(8):561-569.
29. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L, Geissler M, Senekowitsch-Schmidtke R, Goke B, Morris JC, et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008, 15(3):214-223. 10.1038/sj.gt.3303057, 17989705.
30. Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002, 99(11):3923-3930. 10.1182/blood.V99.11.3923, 12010790.
31. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. NatMed 2006, 12(3):342-347.
32. Chen X, Wu JM, Hornischer K, Kel A, Wingender E. TiProD: the tissue-specific promoter database. Nucleic Acids Res 2006, 34(Database issue):D104-D107. 1347475, 16381824.
33. Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul FM, Asaf R, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal 2010, 12(2):293-304. 10.1089/ars.2009.2793, 19659435.
34. Blain M, Zeng Y, Bendjelloul M, Hallauer PL, Kumar A, Hastings KE, Karpati G, Massie B, Gilbert R. Strong muscle-specific regulatory cassettes based on multiple copies of the human slow troponin I gene upstream enhancer. Hum Gene Ther 2010, 21(1):127-134. 10.1089/hum.2008.208, 19719387.
35. Yew NS, Przybylska M, Ziegler RJ, Liu D, Cheng SH. High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter. Mol Ther 2001, 4(1):75-82. 10.1006/mthe.2001.0415, 11472109.
36. Magnusson T, Haase R, Schleef M, Wagner E, Ogris M. Sustained, high transgene expression in liver with plasmid vectors using optimized promoter-enhancer combinations. J Gene Med 2011, 13(7-8):382-391.
37. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 1995, 55(14):3105-3109.
38. Kwon GS, Fraser ST, Eakin GS, Mangano M, Isern J, Sahr KE, Hadjantonakis AK, Baron MH. Tg(Afp-GFP) expression marks primitive and definitive endoderm lineages during mouse development. Dev Dyn 2006, 235(9):2549-2558. 10.1002/dvdy.20843, 1850385, 16708394.
39. Hurtado Pico A, Wang X, Sipo I, Siemetzki U, Eberle J, Poller W, Fechner H. Viral and nonviral factors causing nonspecific replication of tumor- and tissue-specific promoter-dependent oncolytic adenoviruses. Mol Ther 2005, 11(4):563-577. 10.1016/j.ymthe.2004.10.021, 15771959.
40. Boeckle S, von Gersdorff K, van der Piepen S, Culmsee C, Wagner E, Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J Gene Med 2004, 6(10):1102-1111. 10.1002/jgm.598, 15386739.
41. Kircheis R, Blessing T, Brunner S, Wightman L, Wagner E. Tumor targeting with surface-shielded ligand-polycation DNA complexes. J Control Release 2001, 72(1-3):165-170.
42. Ferrari S, Moro E, Pettenazzo A, Behr JP, Zacchello F, Scarpa M. ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo. Gene Ther 1997, 4(10):1100-1106. 10.1038/sj.gt.3300503, 9415317.
43. Argyros O, Wong SP, Niceta M, Waddington SN, Howe SJ, Coutelle C, Miller AD, Harbottle RP. Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector. Gene Ther 2008, 15(24):1593-1605. 10.1038/gt.2008.113, 18633447.
44. Smrekar B, Wightman L, Wolschek MF, Lichtenberger C, Ruzicka R, Ogris M, Rodl W, Kursa M, Wagner E, Kircheis R. Tissue-dependent factors affect gene delivery to tumors in vivo. Gene Ther 2003, 10(13):1079-1088. 10.1038/sj.gt.3301965, 12808438.
45. Klutz K, Schaffert D, Willhauck MJ, Grunwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ, Senekowitsch-Schmidtke R, Goke B, et al. Epidermal growth factor receptor-targeted (131)I-therapy of liver cancer following systemic delivery of the sodium iodide symporter gene. Mol Ther 2011, 19(4):676-685. 10.1038/mt.2010.296, 3070097, 21245850.
46. Wolschek MF, Thallinger C, Kursa M, Rossler V, Allen M, Lichtenberger C, Kircheis R, Lucas T, Willheim M, Reinisch W, et al. Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 2002, 36(5):1106-1114. 10.1053/jhep.2002.36372, 12395320.
47. Manzini S, Vargiolu A, Stehle IM, Bacci ML, Cerrito MG, Giovannoni R, Zannoni A, Bianco MR, Forni M, Donini P, et al. Genetically modified pigs produced with a nonviral episomal vector. Proc Natl Acad Sci USA 2006, 103(47):17672-17677. 10.1073/pnas.0604938103, 1635978, 17101993.
48. Wong SP, Argyros O, Coutelle C, Harbottle RP. Non-viral S/MAR vectors replicate episomally in vivo when provided with a selective advantage. Gene Ther 2011, 18(1):82-87. 10.1038/gt.2010.116, 20739959.
49. Rupprecht S, Lipps HJ. Cell cycle dependent histone dynamics of an episomal non-viral vector. Gene 2009, 439(1-2):95-101.
50. Nehlsen K, Broll S, Bode J. Replicating minicircles: generation of nonviral episomes for the efficient modification of dividing cells. Gene TherMolBiol 2006, 10:233-244.
51. Jenke AC, Eisenberger T, Baiker A, Stehle IM, Wirth S, Lipps HJ. The nonviral episomal replicating vector pEPI-1 allows long-term inhibition of bcr-abl expression by shRNA. HumGene Ther 2005, 16(4):533-539.
52. House BL, Mortimer MW, Kahn ML. New recombination methods for Sinorhizobium meliloti genetics. Appl Environ Microbiol 2004, 70(5):2806-2815. 10.1128/AEM.70.5.2806-2815.2004, 404432, 15128536.
53. Russ V, Elfberg H, Thoma C, Kloeckner J, Ogris M, Wagner E. Novel degradable oligoethylenimine acrylate ester-based pseudodendrimers for in vitro and in vivo gene transfer. Gene Ther 2008, 15(1):18-29. 10.1038/sj.gt.3303046, 17960160.